Advertisement
Advertisement
AQST
Aquestive Therapeutics, Inc. Common Stock
4.32
USDSponsored
+0.09
+2.13%
May 08, 15:59 UTC -4
Closed
Pre-Market
4.29
-0.03
-0.79%
AQST Earnings Reports
Positive Surprise Ratio
AQST beat 15 of 31 last estimates.
48%
Next Report
In 2 Days
Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
$11.11M
/-$0.13
Implied change from Q4 25 (Revenue/ EPS)
-14.61%
/-13.33%
Implied change from Q1 25 (Revenue/ EPS)
+27.45%
/-45.83%
Aquestive Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 04, 2026, AQST reported earnings of -0.15 USD per share (EPS) for Q4 25, missing the estimate of -0.13 USD, resulting in a -10.95% surprise. Revenue reached 13.02 million, compared to an expected 13.55 million, with a -3.95% difference. The market reacted with a -2.52% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.13 USD, with revenue projected to reach 11.11 million USD, implying an decrease of -13.33% EPS, and decrease of -14.61% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Aquestive Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Aquestive Therapeutics, Inc. Common Stock reported EPS of -$0.15, missing estimates by -10.95%, and revenue of $13.02M, -3.95% below expectations.
How did the market react to Aquestive Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -2.52%, changed from $4.37 before the earnings release to $4.26 the day after.
When is Aquestive Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for Aquestive Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Aquestive Therapeutics, Inc. Common Stock is expected to report EPS of -$0.13 and revenue of $11.11M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement